- |||||||||| letrozole / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., indomethacin / Generic mfg.
Hypercalcemia as A Result of Uterine Leiomyomas: A Case Report (ENDOExpo; Poster Floor) - Jun 2, 2026 - Abstract #ENDO2026ENDO_3813;
This case emphasizes that benign gynecological conditions should be considered in the differential diagnosis of hypercalcemia in the absence of an identifiable malignancy. In conclusion, Leiomyomatosis is a rare cause of PTH-rP mediated hypercalcemia and can resolve entirely following surgical resection.
- |||||||||| abiraterone acetate / Generic mfg.
Disrupted Adrenal Steroidogenesis with Abiraterone Therapy: Concurrent Mineralocorticoid Excess and Adrenal Insufficiency (AI) (ENDOExpo; Poster Floor) - Jun 2, 2026 - Abstract #ENDO2026ENDO_3573;
It blocks 17-alpha hydroxylation of pregnenolone and progesterone which precede cortisol and androgen synthesis...Case: An 86-year-old man with metastatic prostate cancer, status post radical prostatectomy on leuprolide, abiraterone, and prednisone presented with acute encephalopathy...Empiric antibiotics, acyclovir and Dexamethasone were started...Dexamethasone was stopped; stress doses of hydrocortisone were started and eventually converted to maintenance prednisone therapy for presumed primary AI due to CYP17A1 inhibitor use...Hypertension and hypokalemia were successfully treated with spironolactone, a mineralocorticoid receptor antagonist... Our case highlights the consequences of Abiraterone therapy in the absence of a long-acting GC; the need for patient education, and recommendations for appropriate management.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
Can Exogenous Testosterone Exposure Trigger Persistent Premature Pubarche ? (ENDOExpo; Poster Floor) - Jun 2, 2026 - Abstract #ENDO2026ENDO_3364;
A leuprolide stimulation test done did not show central precocious puberty...To our knowledge, there are no current publications that have found a relationship between exogenous testosterone exposure and early pubarche which has persisted after removal of exposure. In our opinion, for patients with premature pubarche due to exogenous testosterone exposure, long term follow up is necessary.
- |||||||||| Prolia (denosumab) / Amgen
Are Men with Prostate Cancer Treated with Androgen Deprivation Therapy Being Appropriately Screened for Bone Loss? (ENDOExpo; Poster Floor) - Jun 2, 2026 - Abstract #ENDO2026ENDO_2927;
ASCO recommends treatment with an osteoclast inhibitor, either denosumab or bisphosphonate, if patients meet a clinical diagnosis of osteoporosis, or a T-score -2.5 and a FRAX score 10-year probability of a major osteoporotic fracture >20% or hip fracture >3%...Methods We conducted a retrospective chart review of 850 patients with ICD-10 code C61 (prostate cancer) and NDC code for leuprolide, 0074-3642-03, that were seen in the primary care, endocrinology, oncology, or urology clinics in our hospital system July 2020-July 2025...Unlike previous studies, our study did not show a reduction in fracture rates in those receiving baseline DXA scan. Further education for those that treat men with prostate cancer after ADT is needed to improve screening rates and treatment of osteoporosis in these patients.
- |||||||||| An Unexpected Thyroid Detour in Reproductive Care (ENDOExpo; Poster Floor) - Jun 2, 2026 - Abstract #ENDO2026ENDO_2575;
Case A 37-year-old woman with a history of infertility and uterine leiomyoma presented with two weeks of worsening anterior neck pain and swelling associated with odynophagia, with symptoms unresponsive to acetaminophen and naproxen...She was treated with propranolol 10 mg TID and a 7-day prednisone taper, with advice to defer further infertility treatment until euthyroidism was achieved...It highlights leuprolide-induced thyroiditis as an underrecognized complication of GnRH agonist therapy, particularly in patients undergoing fertility treatment, where thyroid dysfunction may affect reproductive outcomes. Clinicians should maintain a high index of suspicion for thyroid dysfunction after leuprolide exposure, and baseline thyroid evaluation with close biochemical monitoring may facilitate early recognition and management.
- |||||||||| Orgovyx (relugolix) / Takeda, Sumitomo Pharma, Pfizer
A Case of Leydig Cell Tumor Causing Persistent Hyperandrogenism in a Patient on Androgen Deprivation Therapy (ENDOExpo; Poster Floor) - Jun 2, 2026 - Abstract #ENDO2026ENDO_2541;
Clinicians should maintain a high index of suspicion for thyroid dysfunction after leuprolide exposure, and baseline thyroid evaluation with close biochemical monitoring may facilitate early recognition and management. He was started on leuprolide, abiraterone, and underwent radiation therapy...During the second year of treatment, PSA rose to 1.24 ng/mL with testosterone reported up to 700-800 ng/dL range (250
- |||||||||| leuprolide acetate for depot suspension / Generic mfg., zoledronic acid / Generic mfg.
Monostotic Fibrous Dysplasia of Skull (ENDOExpo; Poster Floor) - Jun 2, 2026 - Abstract #ENDO2026ENDO_1803;
Prostate biopsy confirmed high grade Gleason 8 prostate cancer which was treated with radiation and leuprolide...Vitamin D supplementation and therapy with zoledronic acid for pain are planned...Treatment of craniofacial FD(CFFD) needs multidisciplinary approach with goals to prevent function loss (hearing or vision impairment), reducing facial deformity and long-term morbidity. Any active disease with rapid growth, new pain, functional loss warrants surgical referral.
- |||||||||| Perjeta (pertuzumab) / Roche
Transient Thyroid Index Abnormalities in a Patient Taking Biotin: Signal or Laboratory Noise ? (ENDOExpo; Poster Floor) - Jun 2, 2026 - Abstract #ENDO2026ENDO_1342;
Patient remained on ovarian suppression with leuprolide and an aromatase inhibitor...Isolated TSH suppression on Roche-based assays should be interpreted cautiously when other thyroid indices remain normal, especially in a patient with normal renal function. Points to be discussed
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
A Cautionary Case of PIT-1 Lineage Pituitary Adenoma with Rapid Regrowth (ENDOExpo; Poster Floor) - Jun 2, 2026 - Abstract #ENDO2026ENDO_1111;
Rapid postoperative regrowth underscores the importance of close radiographic surveillance, timely visual field assessment, and early multidisciplinary management. It also raises consideration for earlier adjuvant therapy in select PIT-1 adenomas exhibiting invasive or proliferative characteristics.
- |||||||||| terazosin / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
Clinical, Journal: Terazosin as a Non-Hormonal Treatment for Endometriosis. (Pubmed Central) - May 13, 2026
NF-?B decreased in tissue and serum (p < 0.001) but not in peritoneal fluid (p = 0.206). Overall, terazosin produced leuprolide-like molecular benefits without hormonal suppression, supporting repurposing as a candidate non-hormonal therapy, while highlighting the need for longer-duration studies and randomized clinical trials given model and pain-assessment limitations.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
Efficacy and Safety of 3-Month Leuprorelin Acetate Microspheres in Chinese Children with Central Precocious Puberty: A Prospective Multicenter Study (Room W187) - May 11, 2026 - Abstract #ENDO2026ENDO_920;
Overall, terazosin produced leuprolide-like molecular benefits without hormonal suppression, supporting repurposing as a candidate non-hormonal therapy, while highlighting the need for longer-duration studies and randomized clinical trials given model and pain-assessment limitations. The 3-month leuprorelin acetate microsphere formulation effectively suppressed the pituitary-gonadal axis and slowed pubertal progression in children with CPP, with a tolerable safety profile.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg., medroxyprogesterone injection / Generic mfg.
Journal: Success of menstrual suppression for patients with obstructive Mullerian anomalies. (Pubmed Central) - May 11, 2026
Many patients reported effective suppression with COC pills containing 30 mcg of EE. Almost half of the patients reported poor pain control with the initial menstrual suppression method.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
Trial completion date, Trial primary completion date: Comparison of the Therapeutic Effects of Vaginal Repair With Leuprorelin and Vaginal Repair in the Treatment of Cesarean Section Scar Defect (clinicaltrials.gov) - Apr 24, 2026
P=N/A, N=94, Recruiting,
Overall, this work provides mechanistic insight into the structure-performance relationship of microfluidic manipulated core-shell PLGA microspheres for long-term release of LA and establishes a rational foundation for the design of predictable long-acting peptide delivery systems. Trial completion date: Apr 2026 --> Dec 2027 | Trial primary completion date: Apr 2025 --> Apr 2027
- |||||||||| Nubeqa (darolutamide) / Bayer, Orion Corp
A phase 2 study of darolutamide plus leuprolide acetate in hormone therapy (E450b) - Apr 21, 2026 - Abstract #ASCO2026ASCO_2941;
P2
Trial completion date: Nov 2027 --> Sep 2028 Funded by U.S. National Institutes of Health Bayer Clinical Trial Registration Number: NCT05669664 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- |||||||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Trial primary completion date: ADEPT: A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (clinicaltrials.gov) - Apr 2, 2026
P2, N=393, Active, not recruiting,
Its oral formulation, once-daily dosing, and rapid reversibility position relugolix as a promising therapeutic option, especially in individualized treatment strategies. Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2026 --> Mar 2026
- |||||||||| Network-based discovery of tumor-checkpoint inverter drugs targeting pancreatic ductal adenocarcinoma cell states and macrophage reprogramming (Section 16) - Mar 17, 2026 - Abstract #AACR2026AACR_5807;
Predicted MR-inversion scores correlated with experimental dose-response profiles in cell lines selected via OncoMatch.Together, these results establish a mechanistic link between tumor-intrinsic transcriptional states and macrophage immunosuppression, while identifying mutation-agnostic, state-specific drugs capable of reprogramming both tumor and immune compartments. This work provides a generalizable framework for network-based drug repurposing to overcome transcriptional plasticity and immune resistance in PDAC.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg., leuprolide acetate injection / Generic mfg.
Journal: Sterile abscess following intramuscular leuprolide acetate injection for endometriosis: A case report. (Pubmed Central) - Mar 13, 2026
LA is a common treatment for refractory endometriosis in pediatric patients, but providers may be unaware of the risk of sterile abscess. We did not identify any predictive or preventative factors but propose that prior treatment may have increased risk in this case.
- |||||||||| Xtandi (enzalutamide) / Pfizer, Astellas
Duration of treatment suspension among all randomized patients in EMBARK (206) - Mar 13, 2026 - Abstract #AUA2026AUA_3647;
P3
Despite nearly 6 months longer tx suspension, enza combo demonstrated superior OS compared with leuprolide alone. This finding supports the potential for intermittent tx with enza combo to maintain efficacy while reducing tx burden in pts with hrBCR prostate cancer.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg., triptorelin / Generic mfg.
PHARMACOECONOMIC EVALUATION OF DIFFERENT GONADOTROPIN-RELEASING HORMONE ANALOGS IN THE TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY IN CHINA () - Mar 6, 2026 - Abstract #ISPOR2026ISPOR_760;
Leuprorelin-3M demonstrates economic advantages over leuprorelin 1M and goserelin 1M by reducing the number of injections and lowering costs, benefiting multiple stakeholders including healthcare providers, patients and payers. Leuprorelin-3M has economic advantages over leuprorelin-1M and triptorelin-1M by reducing the number of hospital visits and lowering treatment costs, benefiting multiple parties including healthcare providers, patients and payers.
- |||||||||| Two Roads to Shock: A Mediastinal Mass With Dual Hemodynamic Impact (Area G, Halls WA2-WA3 (Level II, OCCC West Concourse); Poster Board # P1257) - Mar 3, 2026 - Abstract #ATS2026ATS_7337;
Pre-phase treatment was started with bortezomib and prednisone followed by daunorubicin and bortezomib per the AALL1231 protocol...Extrinsic compression of the pulmonary artery causing RV failure, elevated pulmonary artery pressure, and normal wedge define group IV pulmonary hypertension, which this patient developed. Treatment would be best aimed at relieving the obstruction through surgical interventions or chemo/radiation therapy.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
Recurrent Massive Bilateral Catamenial Hemothoraces With Buffalo Chest Syndrome (Area D, Halls WA2-WA3 (Level II, OCCC West Concourse); Poster Board # P613) - Mar 3, 2026 - Abstract #ATS2026ATS_6663;
She has previously failed Depo-Lupron and combined hormonal contraceptives...TES remains diagnostically and therapeutically challenging due to its rarity, underrecognized menstrual correlation, and high recurrence rates despite surgery. This underscores the importance of clinical awareness and multidisciplinary collaboration in ensuring timely diagnosis and optimizing outcomes in these patients.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
Refractory Catamenial Pneumothorax Demonstrating Diagnostic and Therapeutic Challenges (Area D, Halls WA2-WA3 (Level II, OCCC West Concourse); Poster Board # P608) - Mar 3, 2026 - Abstract #ATS2026ATS_6658;
Despite initiation of leuprolide for prevention, she recently developed a recurrent pneumothorax with tension physiology, requiring repeat VATS with total pleurectomy and redo-pleurodesis...Despite repeated surgical intervention and hormonal suppressive therapy, our patient continued to have recurrent pneumothoraces. In refractory cases such as this, surgically-induced menopause with hysterectomy and bilateral salpingo-oophorectomy has been used with mixed success, emphasizing the need for further study in this population.
- |||||||||| letrozole / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
A Rare Case of Pneumonitis Associated With Leuprolide and Letrozole Therapy for Breast Cancer (Area B, Halls WA2-WA3 (Level II, OCCC West Concourse); Poster Board # P234) - Mar 3, 2026 - Abstract #ATS2026ATS_2014;
While in two cases, the causative effect of leuprolide on pneumonitis is obscured by other concomitant medications, three other cases suggest both letrozole and leuprolide play direct roles through an unknown etiology. We report a case of delayed onset letrozole and leuprolide induced pneumonitis that responded well to high dose corticosteroid therapy.
- |||||||||| prednisone / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
Nicolau Syndrome in a Child: A Rare Injection-Related Complication (Colorado Convention Center (Lobby C, Poster Center 1)) - Mar 2, 2026 - Abstract #AAD2026AAD_2276;
We present a pediatric case of NS following IM leuprolide...He was treated with antihistamines, NSAIDs, and a prednisone injection...Although etiology remains unclear, NS is considered an unpredictable complication independent of number of injections or medication type, dose, or injection frequency, and recurrence is not expected. This case adds to limited pediatric literature, highlights diagnostic challenges, and supports continued IM injection use when clinically indicated.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg., bicalutamide / Generic mfg.
Initial experience with bicalutamide + leuprorelin acetate combination therapy for androgen receptor-positive salivary gland cancer (Poster venue | Pacifico Yokohama Exhibition Hall D) - Mar 2, 2026 - Abstract #JSMO2026JSMO_1407;
Even patients with comorbidities such as chronic obstructive pulmonary disease (COPD) and cerebellar infarction achieved PR and were able to continue treatment. [Conclusions] This study suggests that CAB therapy in elderly patients with comorbidities such as COPD who are not candidates for cytotoxic anticancer drug treatment may be able to continue treatment effectively.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg., abiraterone acetate / Generic mfg., bicalutamide / Generic mfg.
Target Hormonal Pathway: Androgen Deprivation Therapy for Patients with AR-Positive Metastatic Salivary Gland Carcinoma (Poster venue | Pacifico Yokohama Exhibition Hall D) - Mar 2, 2026 - Abstract #JSMO2026JSMO_1394;
[Conclusions] Metastatic salivary gland carcinoma is associated with a poor prognosis making the exploration of new treatment options essential. Previous studies have suggested potential benefits of androgen deprivation therapy; however further research is needed to fully evaluate its efficacy and establish the role in management.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg., bicalutamide / Generic mfg.
Favorable Response to Androgen Deprivation in a Lung Salivary Gland-Type Tumor with Low Androgen Receptor Expression (Poster venue | Pacifico Yokohama Exhibition Hall D) - Mar 2, 2026 - Abstract #JSMO2026JSMO_1386;
With the use of ADT, most studies report response if AR positivity is more than 30%. This case provides evidence that ADT may offer clinical benefit in tumors with low AR expression, and its use should be considered when other systemic options are inaccessible or contraindicated.
- |||||||||| Orserdu (elacestrant) / Menarini
POP-ELA: a short-term preoperative, phase II, window-of-opportunity study, evaluating activity and safety of Elacestrant with and without ovarian function suppression (OFS) in premenopausal patients with stage I (Exhibition Area) - Feb 25, 2026 - Abstract #ESMOBC2026ESMO_BC_468;
P2
While tamoxifen remains a commonly used option for lowrisk premenopausal pts, side effects and contraindications limit its use, and OFS-related side effects limit tolerability and adherence...Pts will be randomized 1:1 to receive either elacestrant 345 mg daily for 28 days or the same regimen plus subcutaneous Leuprorelin 3.75 mg on day 1...Secondary endpoints include complete cell cycle arrest (Ki67 < 2.7%), geometric mean Ki67 reduction, MRI-based clinical response, pathological complete response rate, hormonal level changes (estradiol, FSH, LH) and safety. Enrollment began in October 2025 and is ongoing across two centers in France.
- |||||||||| Preclinical, Journal: Combination Hormonal Drug Therapy Inhibits In (Pubmed Central) - Feb 20, 2026
MHC I activity and DNA damage response were upregulated. This anti-hormonal drug regimen for AGCT merits prospective investigation.
|
